2.16

24.14% 0.42

After Hours: 2.11 -0.05 -2.31%

Sangamo Therapeutics Inc (SGMO)

Overview News Price History Option Chain Financials Discussions Forecast

Sangamo Therapeutics Inc stock is traded at $2.16, with a volume of 9.34M. It is up +24.14% in the last 24 hours and up +176.57% over the past month. Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Previous Close:

$1.74

Open:

$1.81

24h Volume:

9.34M

Relative Volume:

1.08

Market Cap:

$449.76M

Revenue:

$176.23M

Net Income/Loss:

$-257.83M

P/E Ratio:

-1.4897

EPS:

-1.45

Net Cash Flow:

$-246.00M

1W Performance:

+8.00%

1M Performance:

+176.57%

6M Performance:

+288.63%

1Y Performance:

+369.57%

1-Day Range:

$1.72

$2.175

1-Week Range:

$1.68

$2.175

52-Week Range:

$0.2911

$2.30

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name

Sangamo Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(510) 970-6000

Address

501 CANAL BLVD., RICHMOND, CA

Employee

405

Twitter

@sangamotx

Next Earnings Date

2024-10-30

Latest SEC Filings

SGMO's Discussions on Twitter

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Jun-13-22	Resumed	Wedbush	Neutral
May-04-21	Initiated	RBC Capital Mkts	Outperform
Jan-07-21	Resumed	Guggenheim	Neutral
Jan-06-21	Initiated	Stifel	Hold
Dec-16-20	Resumed	H.C. Wainwright	Buy
Sep-08-20	Initiated	BofA Securities	Buy
Jul-07-20	Initiated	SunTrust	Buy
Aug-26-19	Initiated	H.C. Wainwright	Buy
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-04-15	Initiated	Wells Fargo	Outperform
Oct-23-15	Resumed	Jefferies	Buy
May-03-13	Initiated	BioLogic Equity Research	Sell
Feb-23-11	Reiterated	JMP Securities	Mkt Outperform
Jul-29-10	Reiterated	Wedbush	Outperform
Oct-19-09	Initiated	Brean Murray	Sell
Oct-07-09	Reiterated	Leerink Swann	Outperform
Aug-25-09	Reiterated	JMP Securities	Mkt Outperform

View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

03:59 AM

Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

03:59 AM

10:07 AM

HC Wainwright Forecasts Strong Price Appreciation for Sangamo Therapeutics (NASDAQ:SGMO) Stock - MarketBeat

10:07 AM

03:51 AM

Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com

03:51 AM

Nov 04, 2024

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan

Nov 04, 2024

Nov 01, 2024

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance

Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World

Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat

Nov 01, 2024

Oct 26, 2024

StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News

Oct 26, 2024

Oct 25, 2024

Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News

Oct 25, 2024

Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com

Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK

Oct 24, 2024

Oct 23, 2024

4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga

Oct 23, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St

Oct 23, 2024

Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter

Oct 23, 2024

Oct 22, 2024

Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN

Oct 22, 2024

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart

Oct 22, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Oct 22, 2024

Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Oct 22, 2024

Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug - MarketWatch

Oct 22, 2024

Sangamo stock rallies 37% on FDA update for Fabry disease drug (NASDAQ:SGMO) - Seeking Alpha

Oct 22, 2024

CBER’s lean into accelerated approval slashes three years from Sangamo gene therapy - BioCentury

Oct 22, 2024

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire

Oct 22, 2024

Oct 21, 2024

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec… Trifecta Soon? (NASDAQ:SGMO) - Seeking Alpha

Oct 21, 2024

Oct 17, 2024

Cubist Systematic Strategies LLC Purchases Shares of 185,813 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Oct 17, 2024

Oct 15, 2024

Are Smart Investors Making the Right Decision? Sangamo Therapeutics Inc (SGMO) - SETE News

Oct 15, 2024

Sangamo Therapeutics Inc Inc. (SGMO) Price Performance: The Role of Supply and Demand - The InvestChronicle

Oct 15, 2024

Oct 14, 2024

Observations on the Sangamo Therapeutics Inc (NASDAQ:SGMO) Growth Curve - US Post News

Oct 14, 2024

Oct 11, 2024